bs-5419R **[Primary Antibody]**

phospho-Tau (Thr212) Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 4137 **SWISS:** P10636

Target: Tau (Thr212)

Immunogen: KLH conjugated Synthesised phosphopeptide derived from human Tau around the phosphorylation site of Thr212: SR(p-T)PS.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: Tau proteins are important Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Tau proteins subcellular located in the axons of neurons, in the cytoso l and in association with plasma membrane components. It expressed in neurons. PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.

Applications: **WB** (1:500-2000)
IHC-P (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)
ELISA (1:5000-10000)

Reactivity: Human, Mouse (predicted: Rat, Rabbit, Cow, Dog, Horse)

Predicted MW.: 83 kDa

Subcellular Location: Cell membrane ,Cytoplasm

SELECTED CITATIONS

- **[IF=5.273]** Xin Liu. et al. An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease. NEUROPHARMACOLOGY. 2023 Jul;232:109525 IF,ICC,WB ;Mouse,Human. 37004752
- **[IF=3.742]** Bo Pang. et al. The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation. PHYSIOL BEHAV. 2023 May;263:114134 WB ;Rat. 36809844